Loading...

CRMD CORMEDIX INC US FDA Inspections 8-K Filing

CRMD

CRMD

CORMEDIX INC

(CRMD)

2023 8-K

Show Summary

Summary

Equity Offerings

Market Expansion

Financial Statements

Accountant Change

Financial Results

Financial Results

Stockholder Meeting

Q3 Financial Results

Q2 Financial Results

Earnings Reports

Earnings Report

Departure of Dr. Phoebe Mounts

Departure of Directors

Financial Results Announcement

Underwriting Agreement

Earnings Reports

Appointment of Director

Financial Results Announcement

External Links:

CorMedix Inc. announced that the resubmission of the New Drug Application for DefenCath has been accepted for filing by the FDA with a target action date of November 15, 2023.

AI Assistant

CORMEDIX INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.